NLRP3 inflammasome inhibitor. Inhibits formation of NLRP3 inflammasome and IL-1β release in LPS and ATP-stimulated mouse macrophages and cardiomyocytes in vitro. Inhibits NLRP3 activation in mouse acute myocardial infarction and peritonitis models without affecting plasma glucose levels. Glyburide synthetic intermediate.
Marchetti et al (2014) A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J.Cardiovasc.Pharmacol. 63 316 PMID:24336017 |Fulp et al (2018) Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization. J.Med.Chem. 61 5412